William K. Heiden's most recent trade in Atara Biotherapeutics Inc was a trade of 7,828 Common Stock done . Disclosure was reported to the exchange on June 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atara Biotherapeutics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 7,828 | 22,188 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Macrogenics Inc | William K. Heiden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2025 | 6,500 | 0 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | William K. Heiden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2025 | 6,500 | 11,000 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 3,750 | 3,750 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 16,500 | 16,500 | - | - | Stock Option (right to buy) | |
| Macrogenics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 6,500 | 6,500 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | William K. Heiden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 4,500 | 4,500 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | William K. Heiden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 4,500 | 0 | - | - | Restricted Stock Unit | |
| Atara Biotherapeutics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 150,000 | 359,000 (0%) | 0% | 0 | Common Stock | |
| Atara Biotherapeutics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 79,500 | 79,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 57,000 | 109,000 (0%) | 0% | 0 | Common Stock | |
| Atara Biotherapeutics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 31,500 | 31,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,500 | 52,000 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2022 | 36,000 | 36,000 | - | - | Stock Option (right to buy) | |
| Atara Biotherapeutics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | William K. Heiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,000 | 31,500 (0%) | 0% | 0 | Common Stock |